Cargando…

Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities

Drug incompatibilities are considered as one of the most critical problems in intensive care units. In the current study, the ability of nanomaterials to prevent drug incompatibilities in clinical settings has been investigated. As a proof-of-concept, the ability of niosomes to prevent physical and...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Hebatallah B., El-Shanawany, Sohair M., Hamad, Mostafa A., Elsabahy, Mahmoud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524940/
https://www.ncbi.nlm.nih.gov/pubmed/28740102
http://dx.doi.org/10.1038/s41598-017-06955-w
_version_ 1783252556242223104
author Mohamed, Hebatallah B.
El-Shanawany, Sohair M.
Hamad, Mostafa A.
Elsabahy, Mahmoud
author_facet Mohamed, Hebatallah B.
El-Shanawany, Sohair M.
Hamad, Mostafa A.
Elsabahy, Mahmoud
author_sort Mohamed, Hebatallah B.
collection PubMed
description Drug incompatibilities are considered as one of the most critical problems in intensive care units. In the current study, the ability of nanomaterials to prevent drug incompatibilities in clinical settings has been investigated. As a proof-of-concept, the ability of niosomes to prevent physical and chemical incompatibilities that occur upon mixing acyclovir and vancomycin during management of acute meningitis has been explored. Nanosized spherical particles loaded separately with either vancomycin or acyclovir, with high entrapment efficiency (ca. 46–56%), could be prepared, and sustained release of their entrapped cargoes have been demonstrated over time. We have shown that precipitation, degradation and loss of biological activity of drugs occurred upon mixing solutions of the free drugs. On the contrary, drugs loaded separately inside niosomal structures exhibited high stability, exceptional physical and chemical compatibilities for up to 48 h with complete preservation of the antimicrobial activity of vancomycin. This study opens a venue for a new spectrum of applications of nanomaterials in preventing clinically significant drug incompatibilities, aiming at the reduction of adverse reactions, cost and hospitalization period, and improvement of patient compliance and therapeutic outcomes.
format Online
Article
Text
id pubmed-5524940
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-55249402017-07-26 Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities Mohamed, Hebatallah B. El-Shanawany, Sohair M. Hamad, Mostafa A. Elsabahy, Mahmoud Sci Rep Article Drug incompatibilities are considered as one of the most critical problems in intensive care units. In the current study, the ability of nanomaterials to prevent drug incompatibilities in clinical settings has been investigated. As a proof-of-concept, the ability of niosomes to prevent physical and chemical incompatibilities that occur upon mixing acyclovir and vancomycin during management of acute meningitis has been explored. Nanosized spherical particles loaded separately with either vancomycin or acyclovir, with high entrapment efficiency (ca. 46–56%), could be prepared, and sustained release of their entrapped cargoes have been demonstrated over time. We have shown that precipitation, degradation and loss of biological activity of drugs occurred upon mixing solutions of the free drugs. On the contrary, drugs loaded separately inside niosomal structures exhibited high stability, exceptional physical and chemical compatibilities for up to 48 h with complete preservation of the antimicrobial activity of vancomycin. This study opens a venue for a new spectrum of applications of nanomaterials in preventing clinically significant drug incompatibilities, aiming at the reduction of adverse reactions, cost and hospitalization period, and improvement of patient compliance and therapeutic outcomes. Nature Publishing Group UK 2017-07-24 /pmc/articles/PMC5524940/ /pubmed/28740102 http://dx.doi.org/10.1038/s41598-017-06955-w Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Mohamed, Hebatallah B.
El-Shanawany, Sohair M.
Hamad, Mostafa A.
Elsabahy, Mahmoud
Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities
title Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities
title_full Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities
title_fullStr Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities
title_full_unstemmed Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities
title_short Niosomes: A Strategy toward Prevention of Clinically Significant Drug Incompatibilities
title_sort niosomes: a strategy toward prevention of clinically significant drug incompatibilities
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524940/
https://www.ncbi.nlm.nih.gov/pubmed/28740102
http://dx.doi.org/10.1038/s41598-017-06955-w
work_keys_str_mv AT mohamedhebatallahb niosomesastrategytowardpreventionofclinicallysignificantdrugincompatibilities
AT elshanawanysohairm niosomesastrategytowardpreventionofclinicallysignificantdrugincompatibilities
AT hamadmostafaa niosomesastrategytowardpreventionofclinicallysignificantdrugincompatibilities
AT elsabahymahmoud niosomesastrategytowardpreventionofclinicallysignificantdrugincompatibilities